Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Share
Our SDG Commitment
At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our U.N. SDG 2020 Commitment complements our Health for Humanity 2020 Goals, which focus our citizenship and sustainability efforts where we believe Johnson & Johnson can achieve the greatest impact.
The Johnson & Johnson SDG Commitment
Johnson & Johnson was one of the first major companies to make a public commitment to the SDGs in 2016. Our SDG Commitment extends and significantly builds upon our previous U.N. Millennium Development Goals (MDG) Commitment in 2010 that improved the lives of more than 400 million women and children over the five-year time frame and furthers our long legacy of work in public health around the world.
Our commitment to dedicate our expertise, ideas and ingenuity to catalyze efforts toward achieving SDG 3 (Good Health and Well-being) SDG 5 (Gender Equality) and SDG 17 (Partnership for the Goals) reflects the Company’s unique constellation of strengths.
Our Five Focus Areas
The Johnson & Johnson SDG commitment focuses on five areas in which the Company is uniquely positioned to create sustainable and scalable impact:
Accelerating Progress Towards Our SDG Goals
More From Johnson & Johnson
With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.
The large-scale, pivotal, multi-country Phase 3 trial ( ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants. Given the high incidence of COVID-19 among the general population in the countries where the trial is being conducted, this number of participants will be sufficient to generate the data needed to determine the efficacy and safety of the Company’s investigational COVID-19 vaccine candidate. Johnson & Johnson expresses its thanks to all participants, trial sites and health care professionals involved in the ENSEMBLE study.
With COVID-19 dominating the news this year, chances are you've also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.
